Healthcare
Sumitomo Pharma Co., Ltd.(DNPUF)
Live Price
Offline$9.41
+0.00% today
Window Change
-7.29%
Window
May 29, 2026 โ Jun 23, 2026
- Market Cap
- $687.11B
- Revenue Growth
- +26.8%
- EPS Growth
- +107.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 17 bars ยท May 29, 2026 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sumitomo Pharma Co., Ltd. (DNPUF) is a Healthcare stock with a market cap of $687.11B and listed on OTC. The stock last traded around $9.41 and down 7.3% across the available one-year price window (May 29, 2026 โ Jun 23, 2026). Baseline metrics include revenue growth of +26.8%, EPS growth of +107.5%, a dividend yield of 0.0%. What stands out right now is revenue +26.8%, EPS +107.5%, free cash flow +101.3% with operating margin 12.9% and ROIC 9.7%. Valuation is more restrained than many high-expectation growth names at P/E 6.2 and price/sales 1.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DNPUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.8% vs +7.6% peer median
Operating Margin
Below sector median
+12.9% vs +19.4% peer median
P/E
Below sector median
6.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 13, 2026 with an EPS surprise of +86.6% and a revenue surprise of +6.0%.
The operating story is still moving forward
Revenue is running at +26.8% and EPS at +107.5%, with operating margin around 12.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
DNPUF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DNPUF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DNPUF Max Drawdown
-12.61%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DNPUF and SPY.
Company Overview
Sumitomo Pharma Co., Ltd.
Other OTC
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
- Leadership
- Toru Kimura
- IPO Date
- Jan 17, 2012
- Employees
- 5.0k
- Street Address
- 6-8, Doshomachi 2-chome
- Mailing
- Osaka, 541-0045
- Region
- Osaka, JP
- Reporting Currency
- USD
- Investor Line
- 81 6 6203 5321
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.2
- EV/EBITDA
- 11.1
- Price/Sales
- 1.5
- Price/Book
- 2.4
Growth
- Revenue
- +26.8%
- EPS
- +107.5%
- Free Cash Flow
- +101.3%
Profitability
- Gross Margin
- 59.2%
- Operating Margin
- 12.9%
- Net Margin
- 24.3%
- ROE
- 48.9%
- ROIC
- 9.7%
Balance Sheet
- Debt/Equity
- 0.90
- Current Ratio
- 1.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.